GLUE Projected Dividend Yield
Monte Rosa Therapeutics Inc ( NASDAQ : GLUE )Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. Co. is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the body's natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. 21 YEAR PERFORMANCE RESULTS |
GLUE Dividend History Detail GLUE Dividend News GLUE Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |